WALTHAM,
Mass., April 5, 2022 /PRNewswire/ -- Fresenius
Medical Care, the world's leading provider of products and services
for individuals with renal diseases, announced today the
appointment of noted clinical researcher and nephrologist
Nwamaka (Amaka) Eneanya, MD as Head
of Strategy and Operations for the company's Global Medical
Office.
Dr. Eneanya was previously an attending nephrologist and
Assistant Professor of Medicine and Epidemiology at the
University of Pennsylvania, where she
served as Director of Health Equity, Anti-Racism, and Community
Engagement in the Nephrology Division. At Fresenius Medical Care
she will report directly to the Global Chief Medical Officer and
serve on the Global Medical Office Executive Leadership Team.
"As both a board-certified clinician and expert researcher, Dr.
Eneanya brings a wealth of knowledge and expertise that will
advance our work in improving outcomes for people living with
kidney disease," said Frank Maddux,
MD, Global Chief Medical Officer of Fresenius Medical Care. "Her
insights regarding health equity, patient-reported outcomes, and
social engagement in healthcare and public health will be key
elements to inform our ongoing medical strategy."
Dr. Eneanya is the co-author of a widely cited article which
argued that when estimating glomerular filtration (eGFR) equations,
it is problematic to assert that organ function differs between
individuals whose physical conditions are essentially identical
except for their race. Published in the prestigious Journal of the
American Medical Association in 2020, the article, along with Dr.
Eneanya's extensive scientific advocacy, helped spark a
national conversation in the U.S. about removing race from the
kidney function algorithm.
The American Society of Nephrology and the National Kidney
Foundation subsequently created a joint task force to reassess the
inclusion of race in eGFR and its implications for the diagnosis
and management of kidney disease patients. The task force, on which
Dr. Eneanya served, recently recommended the immediate adoption of
a new, race-free eGFR equation.
Dr. Eneanya's research has been supported by the National
Institutes of Health and the American Society of Nephrology. She
has received numerous accolades including the Radhika Srinivasan Award for Humanism &
Professionalism in Medicine from the University of Pennsylvania last year. In 2020, she
was recognized as a "40 under 40 Leader in Minority Health" by the
National Minority Quality Forum.
A fellow of the American Society of Nephrology, Dr. Eneanya
completed her residency in internal medicine at Brigham and Women's
Hospital in Boston and nephrology
training at the combined Nephrology Fellowship Program at
Massachusetts General Hospital/Brigham and Women's Hospital. She
holds an undergraduate degree from Cornell
University, a medical degree from Meharry Medical College, and a master's degree in
public health from the Harvard T.H. Chan School of Public
Health.
Fresenius Medical Care is the world's leading provider of
products and services for individuals with renal diseases of
which around 3.8 million patients worldwide regularly undergo
dialysis treatment.
Through its network of 4,171 dialysis clinics, Fresenius Medical
Care provides dialysis treatments for approximately 345,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Along with its core business, the Renal Care Continuum,
the Company focuses on expanding in complementary areas and in the
field of critical care. Fresenius Medical Care is listed on the
Frankfurt Stock Exchange (FME) and on the New York Stock Exchange
(FMS).
For more information visit the Company's website at
www.freseniusmedicalcare.com.
Media Contact:
Brad Puffer
T 781-699-3331
Brad.Puffer@freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-appoints-dr-amaka-eneanya-as-head-of-strategy-and-operations-for-companys-global-medical-office-301518139.html
SOURCE Fresenius Medical Care Holdings, Inc.